|
Balance Sheet Cash Flow Statement 1405 Parc-Technologique Blvd. Quebec City, Quebec G1P 4P5, Canada Tel. 418-652-8525 Fax 418-652-0881 |
Type: Public
On the web:
http://www.aeternazentaris.com
Employees:
109
Employee growth: (16.8%)
Æterna Zentaris, formerly Æterna Laboratories, knows seriously ill patients can't wait an eternity for new drugs, so the firm is working to take lead drug candidates through trials and to approvals as quickly as possible. The company's pipeline got a boost from the purchase of Zentaris, which has drugs on the market and a dozen others in development for the treatment of cancer and endocrinology disorders. The firm's flagship drug, Centrotide, is an endocrine therapy used for in vitro fertilization. It is approved in 80 countries and is marketed worldwide (except for Japan) by Merck Serono; Shionogi and Nippon Kayaku market the drug in Japan.
Key numbers for fiscal year ending December, 2008:
Sales: $38.5M
One year growth: (8.5%)
Net income: ($59.8)M
Officers:
Executive Chairman: Jurgen Ernst
President and CEO: Jürgen Engel
SVP and CFO: Dennis Turpin
